POPULARITY
Categories
In this episode of Onc Now, host Jonathan Sackier is joined by Stephen Freedland, Surgical Oncologist at Cedars-Sinai Medical Center, Los Angeles, California, USA, to discuss the intersections of biology, behaviour, and bias in prostate cancer. From diet and exercise to disparities in outcomes and promising data on enzalutamide, Freedland challenges assumptions and advocates for a more holistic, equitable approach to care. Timestamps 01:20 – Background and clinical journey 02:39 – Cancer myths: what needs busting 03:22 – Lifestyle's role in prostate cancer 05:18 – One habit all cancer patients should adopt 06:39 – Yes or No round 10:30 – Diet, obesity, and exercise: the data 13:25 – Mediterranean diet and outcomes 15:30 – Predictive lifestyle factors 16:19 – Racial disparities and root causes 18:35 – Gender-affirming treatment and prostate cancer in trans women 23:20 – Enzalutamide: latest data and developments 25:51 – Broader therapeutic landscape 28:40 – Risk of recurrence 30:19 – Advice for young oncologists 34:00 – Three wishes for the future of prostate cancer care
Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about Northwestern Memorial Hospital being named one of the best hospitals in the U.S., Cubs great Ryne Sandberg losing his battle to prostate cancer, what we should know about prostate cancer, and a new study that shows being physically active […]
The Idaho Urologic Institute introduced a procedure that gives doctors a non-invasive way to target prostate cancer.
Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about Northwestern Memorial Hospital being named one of the best hospitals in the U.S., Cubs great Ryne Sandberg losing his battle to prostate cancer, what we should know about prostate cancer, and a new study that shows being physically active […]
Prostate cancer is the second most diagnosed cancer among men worldwide and remains a leading cause of cancer-related death. While early forms of the disease can usually be treated successfully, advanced cases remain a major challenge. Scientists have now discovered a new potential way to slow the growth of advanced, treatment-resistant prostate cancer. These results were recently published in Volume 16 of Oncotarget by researchers from the University of Cincinnati College of Medicine. Understanding Advanced Prostate Cancer Early-stage prostate cancer can often be treated successfully. Most treatments work by lowering testosterone levels or blocking the hormone from activating the androgen receptor (AR), which drives cancer growth. In some patients, however, the disease progresses to castration-resistant prostate cancer (CRPC). Even with drastic reductions in testosterone levels, the tumors continue to grow at this stage. CRPC is much more difficult to treat, and current therapies such as hormone blockers or chemotherapy typically extend life by only a few months. One reason for this resistance is that cancer cells often switch to a different form of the androgen receptor called AR-V7. This variant remains permanently active, even without testosterone, making hormone-based drugs less effective. Because of this, new treatment strategies that work independently of hormone levels are needed. The Study: Targeting a New Weakness in Prostate Cancer Cells In the study titled “Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells,” researchers Shan Lu and Zhongyun Dong from the University of Cincinnati College of Medicine investigated a new way to block CRPC growth. Full blog - https://www.oncotarget.org/2025/07/29/a-new-way-to-target-resistant-prostate-cancer-cells/ Paper DOI - https://doi.org/10.18632/oncotarget.28722 Correspondence to - Zhongyun Dong - dongzu@ucmail.uc.edu Video short - https://www.youtube.com/watch?v=fiJWZ_fKxgs Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28722 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PCNA, androgen receptor, PCNA inhibitors, AR splicing variants, CRPC To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about Northwestern Memorial Hospital being named one of the best hospitals in the U.S., Cubs great Ryne Sandberg losing his battle to prostate cancer, what we should know about prostate cancer, and a new study that shows being physically active […]
Dr Akila Viswanathan speaks with Dr Sophia Kamran from Harvard Medical School and Dr Constantinos Zamboglou from the German Oncology Center about the latest edition of Seminars in Radiation Oncology focusing on new treatments for advanced prostate cancer.
On this episode host Jonathan Chance talks with Dr. Munir Ghesani, who is a Nuclear Oncologist and the Chief Medical Officer for United Theranostics about (RPT) radiopharmaceutical therapy, which is a treatment for prostate cancer. During the podcast Jonathan and Dr. Ghesani talk about:· What is Theranostics and which prostate cancer patients is are candidates for radiopharmaceuticals.· How is the therapy administered and how the effectiveness is determined.· Are there side effects and how does it compare to alpha emitter radiation therapy.· Plutvicto treatment for metastatic prostate cancer.· The Vision and PSMA Fore trials of targeted radioligand therapy in patients with prostate cancer.· What the future looks like for cancer treatment.Prostate Cancer Aware is a copyrighted production. No content maybe rebroadcast or reproduced without the expressed written consent of the Friedman Sidrow Foundation. For more information about prostate cancer, the PSA test, men's health and Jonathan's inspiring new book Unaware, which is about his battle with prostate cancer. Visit our website at: https://www.iknowmypsa.org Email us at: https://www.iknowmypsa.org/contactus/ Follow Prostate Cancer Aware on social media at: Facebook - https://www.facebook.com/iknowmypsa Twitter - https://twitter.com/iknowmypsa or @iknowmypsa Thank you for listening! Remember, Stay Aware and Stay Healthy.™
“Next-generation sequencing, or NGS, can be used to help us determine if the patient has specific biomarkers we can identify and use to target for treatment. Certain findings can tell us if a particular treatment might work for that patient, and we can see if there are any genetic variants we might have a biomarker targeted agent to use to treat them with,” ONS member Jackie Peterson, MSN, RN, OCN®, NE-BC, MBA, ambulatory nurse manager at the University of Chicago Medical Center in Illinois, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about prostate cancer and biomarker testing. This podcast is sponsored by AstraZeneca and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 180: Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Disorders Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Germline and Somatic Variants: What Is the Difference? Help Patients Understand Genomic Variants of Unknown Significance Prostate Cancer Clinical Trials Don't Reflect Racial Diversity—And It's Getting Worse Over Time Prostate Cancer Disparities Disappear With Equal Access to Care Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations The Case of the Genomics-Guided Care for Prostate Cancer ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing articles: Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management Prostate Cancer: How Nurse Practicioners Can Aid in Disease Diagnosis and Management Oncology Nursing Forum article: Identification of Symptom Profiles in Prostate Cancer Survivors Other ONS Resources: Biomarker Database (refine by prostate cancer or specific biomarkers) Clinical tool/case study: Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Genomics and Precision Oncology Learning Library Huddle Card: Genomic Biomarkers Infographic: Talking to Your Patient About a Germline Variant of Uncertain Significance (VUS) American Cancer Society - Genetic Testing and Counseling for Prostate Cancer Risk American Cancer Society - Prostate Cancer Clinicaltrials.gov National Cancer Institute - Prostate Cancer National Comprehensive Cancer Network ZERO Prostate Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Some of the risk factors for developing prostate cancer include age, race, family history, and certain genetic changes or variants. Prostate cancer has some hereditary components, but most prostate cancer occurs in men without any significant family history of it.” TS 1:31 “Key biomarkers include PSA and prostate cancer gene 3, which is PCA3, and prostate-specific membrane antigen, or PSMA. Other biomarkers that are important for us to test include BRCA1, BRCA2, and Lynch syndrome–associated genes, which are MLH1, MSH2, MSH6, PMS2, and EPCAM. Biomarkers can be collected via your blood, urine, saliva, or tissue samples, so these are different ways that we can test and look for biomarkers in our patients.” TS 3:24 “It does matter how advanced the disease is. Usually, for our castrate-sensitive patients, they respond better to androgen deprivation therapy because that really is slowing down the growth of the cancer by reducing the available testosterone that the cancer needs to grow. Whereas our patients that are more advanced and have castrate-resistant prostate cancer, that cancer will continue to grow despite having the lowered testosterone levels, so they might need additional layers of treatment to really get their cancer under control.” TS 7:50 “When I talk to [patients] about biomarker testing, I tell them it's another tool in our toolbox that we can use to help us determine if they might benefit from other therapy options now or in the future. I tell them that sometimes we'll get a report back with a variant of unknown significance, and basically that means that we don't really know whether or not this has an impact on their health or risk factors for the disease. That can sometimes be a little bit of a concern for these patients, so we just have to reassure them that we're continually doing research around biomarker testing. The science is always advancing, so if there's something that [researchers] find in the future, we'll make them aware of that.” TS 9:08 “One of the biggest topics I think about is the inequity that exists in biomarker testing and research, especially surrounding the African American population. When these tests were developed, that population really wasn't studied as much, so there's not a lot of good data yet to make a decision or impact on those patients and that population.” TS: 12:30
In this episode of the Dr. Geo Prostate Podcast, Dr. Geo welcomes Dr. Mohit Khera, a globally recognized leader in men's health, Professor of Urology and Director of the Executive Health Program at Baylor College of Medicine. With over 160 peer-reviewed publications and decades of clinical experience in testosterone therapy, male infertility, and prostate health, Dr. Khera shares cutting-edge insights on testosterone replacement therapy (TRT), including the rise of oral testosterone like Kyzatrex, and the evolving understanding of testosterone's relationship to prostate cancer.Whether you're considering TRT, recovering from prostate cancer, or supporting a loved one's health journey, this conversation brings clarity to one of men's most pressing health topics.What You'll Learn:The 4 C's framework to determine the best TRT option:Cost, Compliance, Convenience, ConcentrationWhy oral testosterone (Kyzatrex, Tlando, Jatenzo) is gaining traction—and what makes them differentHow Kyzatrex may help preserve fertility by reducing gonadotropin suppressionWhat the TRAVERSE trial revealed about TRT and cardiovascular safetyWhy low testosterone may be linked to more aggressive prostate cancerWhat the latest science says about BAT (Bipolar Androgen Therapy) for advanced prostate cancerThe truth about testosterone's impact on BPH and urinary symptomsWhy total testosterone isn't enough—labs like SHBG, DHT, estradiol, and free testosterone matterKey Insights:TRT doesn't cause prostate cancer — and may even have protective effects in some men.Testosterone is the best barometer of male health—predicting cardiovascular risk, mood, bone density, and more.BAT (Bipolar Androgen Therapy) is showing promise in treating advanced prostate cancer in specific scenarios.Avoid unnecessary aromatase inhibitors and DHT blockers unless clinically indicated.
UCSF's Dr. Cornelia Ding demystifies the prostate cancer pathology report and explains how to read and understand it. The report contains five key sections: patient information, diagnosis and comments, gross description, and any addendums or amendments. It serves multiple purposes—as a medical, legal, and clinical communication tool—and often contains technical language not written for patients. Dr. Ding walks through important terminology such as Gleason score, Grade Groups, and specific diagnostic patterns like intraductal carcinoma, emphasizing how each affects risk assessment and treatment planning. Patients are encouraged to focus on the diagnosis and comment sections and to discuss any unclear details with their doctors. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40797]
UCSF's Dr. Cornelia Ding demystifies the prostate cancer pathology report and explains how to read and understand it. The report contains five key sections: patient information, diagnosis and comments, gross description, and any addendums or amendments. It serves multiple purposes—as a medical, legal, and clinical communication tool—and often contains technical language not written for patients. Dr. Ding walks through important terminology such as Gleason score, Grade Groups, and specific diagnostic patterns like intraductal carcinoma, emphasizing how each affects risk assessment and treatment planning. Patients are encouraged to focus on the diagnosis and comment sections and to discuss any unclear details with their doctors. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40797]
UCSF's Dr. Cornelia Ding demystifies the prostate cancer pathology report and explains how to read and understand it. The report contains five key sections: patient information, diagnosis and comments, gross description, and any addendums or amendments. It serves multiple purposes—as a medical, legal, and clinical communication tool—and often contains technical language not written for patients. Dr. Ding walks through important terminology such as Gleason score, Grade Groups, and specific diagnostic patterns like intraductal carcinoma, emphasizing how each affects risk assessment and treatment planning. Patients are encouraged to focus on the diagnosis and comment sections and to discuss any unclear details with their doctors. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40797]
UCSF's Dr. Cornelia Ding demystifies the prostate cancer pathology report and explains how to read and understand it. The report contains five key sections: patient information, diagnosis and comments, gross description, and any addendums or amendments. It serves multiple purposes—as a medical, legal, and clinical communication tool—and often contains technical language not written for patients. Dr. Ding walks through important terminology such as Gleason score, Grade Groups, and specific diagnostic patterns like intraductal carcinoma, emphasizing how each affects risk assessment and treatment planning. Patients are encouraged to focus on the diagnosis and comment sections and to discuss any unclear details with their doctors. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40797]
AUA2025: Incorporating Genomic Testing and Advanced Imaging for Prostate Cancer Into Your Practice CME Available: https://auau.auanet.org/node/43029 At the conclusion of this activity, participants will be able to: 1. Describe the research that led to the approval of genomic testing for prostate cancer and the implementation of advanced imaging for prostate cancer 2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation 3. State the NCCN guidelines for genomic testing and advanced imaging for prostate cancer 4. Discern the different prognostic endpoints provided by various genomic tests 5. Recognize candidates for, and implications of, germline testing for prostate cancer. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]
Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]
Garry and Tim discuss the Legends Game for Prostate Cancer, where Tim will be coaching the Vics. What is some advice garry has for him - plus they discuss some memories from past LEgends games. Do media people within footy have a bias towards people they are friendly with? And we chat with Joe from Peninsula Kubota. For feedback and questions, email joel.brooks@sen.com.au. Learn more about your ad choices. Visit megaphone.fm/adchoices
Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]
Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]
Dr Rahul Aggarwal and Dr William K Oh and nurse practitioners Ms Monica Averia and Ms Kathleen D Burns discuss the current treatment landscape for prostate cancer and protocols to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.
BUFFALO, NY – July 14, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 25, 2025, titled “Hypoxia induced lipid droplet accumulation promotes resistance to ferroptosis in prostate cancer.” In this study, researchers led by Shailender S. Chauhan and Noel A. Warfel from the University of Arizona discovered that prostate cancer cells survive treatment by storing fats in tiny cellular compartments when oxygen levels are low. This process makes the cancer cells less vulnerable to a type of cell death known as ferroptosis. The findings provide new insight into why prostate tumors often resist therapies and suggest potential strategies to improve treatment outcomes. This study focused on ferroptosis, a form of programmed cell death that relies on iron and lipid oxidation to destroy cancer cells. Researchers tested prostate cancer cells under normal and low oxygen conditions and found that hypoxia, or reduced oxygen levels, allowed cancer cells to build up lipid droplets (LD). These structures act as storage units for fats, shielding cancer cells from oxidative damage and preventing ferroptosis from occurring. The researchers found that this adaptation of prostate cancer cells made them less sensitive to ferroptosis-inducing drugs like Erastin and RSL3, even when these drugs were combined for a stronger effect. The team also reported that hypoxia caused significant changes in lipid metabolism, decreasing the availability of specific fatty acids that normally promote ferroptosis. “Transcriptomic analysis revealed that hypoxia significantly reduced the expression of genes related to incorporating polyunsaturated fatty acids into phospholipids (ACSL4, LPCAT3), and parallel lipidomic analysis demonstrated that hypoxia significantly decreased the levels of the ferroptosis-prone lipid class, phosphatidylethanolamine (PE) and increased production of neutral lipid species, cholesteryl ester (ChE (22:5)) and triglycerides (TG(48:1), TG:(50:4), and TG(58:4)).” This research highlights the importance of the tumor microenvironment, particularly oxygen levels, in shaping how cancer cells respond to therapy. By altering their metabolism and storing lipids, prostate tumors may evade treatments designed to trigger ferroptosis. These findings underscore the need to develop new strategies targeting LD dynamics or lipid metabolism to overcome this resistance. Understanding how prostate cancer (Pca) adapts to survive in hypoxic conditions offers a potential avenue for improving therapies. For example, preventing lipid accumulation in cancer cells or releasing stored fats may restore their sensitivity to ferroptosis and improve the effectiveness of current therapies. This approach could have broader implications for treating other solid tumors that share similar metabolic features. DOI - https://doi.org/10.18632/oncotarget.28750 Correspondence to - Noel A. Warfel - warfelna@arizona.edu, and Shailender S. Chauhan - shailenderc@arizona.edu Video short - https://www.youtube.com/watch?v=xFypDT4ALmc Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28750 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, hypoxia, lipid droplets, ferroptosis, resistance, prostate To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
What if artificial intelligence could help save your erections during prostate cancer surgery?In this groundbreaking episode of the Dr. Geo Prostate Podcast, Dr. Geo sits down with world-renowned urologist and sexual health pioneer Dr. Arthur "Bud" Burnett from Johns Hopkins. Together, they discuss an exciting new frontier in men's health: using AI and intraoperative neuromonitoring to preserve erectile function during prostate cancer surgery.Dr. Burnett shares his four decades of experience and explains how advanced techniques — including real-time nerve mapping and AI-guided signals during surgery — are transforming outcomes for men. Imagine a future where surgeons can “see” and protect the exact nerves critical for erections, like having a GPS guiding them in real time.They also dive into:✅ The evolution of erectile dysfunction treatments — from Yohimbine to Viagra and beyond✅ The history and future of penile implants, including the possibility of app-controlled devices✅ Why nerve-sparing techniques alone may not be enough to preserve function after prostatectomy✅ How AI and precision medicine are changing surgical outcomes and offering men more hopePlus, Dr. Burnett discusses upcoming clinical trials and how men can potentially participate today at Johns Hopkins.
Chapters:00:00Introduction to My Medical Journey02:58The Car Accident and Its Aftermath05:48Life Changes and New Beginnings08:46Couchsurfing and Unexpected Insights12:05Prostate Cancer Diagnosis and Treatment Decisions17:46Navigating Medical Challenges and Surgeries23:48Reflections on Health and Healing30:04Recent Developments and Future OutlookSummary:In this podcast, the host shares a deeply personal narrative about his medical journey, starting from a car accident in 1988 that led to chronic pain and a series of health challenges, including a life-threatening blood clot and a prostate cancer diagnosis. He reflects on significant life changes, including coming out as gay, hosting Couchsurfers, and navigating the complexities of the medical system. The conversation also touches on personal growth, resilience, and the importance of self-advocacy in healthcare. The host concludes with insights gained from a recent road trip and a commitment to continue sharing his journey.Takeaways:The importance of self-advocacy in healthcare.Life can change dramatically due to unexpected events.Couchsurfing provided valuable insights into human connection.Prostate cancer can be slow-growing, requiring careful monitoring.Navigating the medical system can be challenging and frustrating.Personal growth often comes from facing adversity.The mind-body connection plays a crucial role in healing.Sharing personal stories can foster community and support.Travel can be a powerful tool for self-discovery.Maintaining a positive outlook is essential during health challenges.Contact Wilkinson @BecomingWilkinson@gmail.comNote: This is story of my journey, from my perspective. It's not medical advice. For that, you need to contact your own medical professional.
A new report says golf is a big turn off for plenty of kids – and huge numbers of parents don't even try to get their children into the sport. The findings, from American Golf, say the Covid boom hasn't been reflected in interest from Under-18s and we risk “losing an entire generation” without action. Is the future of our game in trouble? Tom Irwin and Steve Carroll, both parents of young children, ask if we need to do more to get our offspring away from YouTube and onto the course. Elsewhere, Tom recounts his mammoth 108-hole marathon as he took part in The Big Golf Race to raise cash for Prostate Cancer, Steve laments a disappointing club championship and we ask whether Lottie Woad should have been given her prize money after the amateur sensationally won the Irish Open on the Ladies European Tour. Are the Rules of Amateur Status fit for purpose? You can donate to NCG's Big Golf Race here: https://biggolfrace.prostatecanceruk.org/fundraising/toms-big-golf-race395 Website: https://www.nationalclubgolfer.com/ X: https://x.com/NCG_com Facebook: https://www.facebook.com/NationalClubGolfer Instagram: https://www.instagram.com/nationalclubgolfer/?hl=en
A team of researchers from the Te Whai Ao Dodd-Walls Centre have developed a potential gamechanger in the detection and diagnosis of prostate cancer.
In this episode, we dive deep into the evolving landscape of prostate cancer screening, diagnosis, and treatment. Our guests— Richard Pullen, EdD, RN and Virginia Holter, DNP, APRN, FNP-BC—join us to clear up the confusion around PSA testing, the role of digital rectal exams, and how new imaging technologies are changing the way we detect prostate cancer. We explore the risk factors that matter most, from age and race to genetic mutations such as BRCA1 and 2, obesity, and even environmental exposures. You'll also hear about the complex decisions patients and physicians face together—from whether or not to get screened, to navigating treatment options such as active surveillance, prostatectomy, or high-intensity focused ultrasound ablation. Importantly, we tackle some often-overlooked topics, including impacts on sexual function and prostate cancer in transgender women. If you're over 40, have a loved one at risk, or just want to understand the science and policy behind one of the most common cancers in men—this episode is a must-listen.
What is the role of PSA for early detection, and how does hormone therapy affect cancer patients? These are questions we dig into in this episode. https://bit.ly/4lC0ZUdIn This Episode:01:32 - Road Trip-South Carolina & Shout Halellujah Potato Salad02:38 - Fighting For Your Life Is Boring - Andrew Reynolds04:44 - Prostate Cancer - Risks and Treatment09:46 - Why Was Biden's Prostate Cancer Detected So Late?14:52 - Signs and Symptoms of Prostate Cancer16:08 - Gleason Scoring for Prostate Cancer Grade19:18 - Hormone Therapy - Androgen Deprivation33:27 - Prostate Cancer and Partners36:21 - OutroAbout 1 in 8 men will be diagnosed with prostate cancer during their lifetime. Prostate cancer is the second-leading cause of cancer death in American men, behind lung cancer. Learn signs and symptoms, the role of PSA (prostate-specific antigen) for early detection and monitoring, how androgen-blocking therapy works, and how it affects patients and their partners.Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org
If you or someone you love is affected by prostate cancer, PROSTAID Calgary (403-455-1916) offers monthly support meetings for prostate cancer patients, survivors, and caregivers, with expert guidance, peer connection, and resources. Visit https://prostaid.org/meetings/ for details. Prostaid Calgary City: Calgary Address: 1600 90 Avenue Southwest Website: https://prostaid.org/
In this episode, UROONCO PCa chief editor Dr. Giancarlo Marra speaks to Prof. Derya Tilki (DE) about the 2025 updates in the EAU Prostate Cancer Guidelines, specifically regarding high risk, locally advanced disease and biochemical recurrence. This discussion includes changes such as the use of PSMA-PET-CT for staging, and updates related to lymphadenectomy.
In today's episode, supported by Bayer, we had the pleasure of speaking with Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS, about the FDA approval of darolutamide (Nubeqa) plus androgen deprivation therapy for patients with metastatic castration-sensitive prostate cancer (mCSPC). Morgans is the medical director of the survivorship program at Dana-Farber Cancer Institute; as well as an associate professor of medicine at Harvard Medical School, both in Boston, Massachusetts. Shore is the medical director of the Carolina Urologic Research Center. In our exclusive interview, Drs Morgans and Shore discussed the significance of this approval; key efficacy, safety, and quality of life data from the pivotal phase 3 ARANOTE trial (NCT04736199); and how this regulatory decision both opens doors for the treatment of more patients and raises questions about the optimal role of darolutamide in the management of mCSPC.
Send us a text | MedStar Georgetown University Hospital was the first hospital on the East Coast to offer CyberKnife technology. Our team is among the world's most experienced CyberKnife sites having treated more than 2,400 patients with prostate cancer and performed more than 35,000 treatments in total. Unlike traditional radiation that's given in 40 sessions over eight to nine weeks, CyberKnife can treat prostate cancer in just five visits. Dr. Jonathan Lischalk, a radiation oncologist at MedStar Georgetown, discusses CyberKnife radiation therapy for treating prostate, and the advantages of CyberKnife over conventional radiation. For an interview with Dr. Jonathan Lischalk, or for more information about this podcast, contact MedStar Georgetown University Hospital Manager Media Relations, Ryan.M.Miller2@Medstar.net. Learn more about Dr. Lischalk. | Learn more at MedStarHealth.org/CyberKnifeNow, or call 202-444-4255.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.
Carbon Emissions in Medicine In this series, the host Catherine Glass welcomes Stacy Loeb, a renowned urologist and lifestyle medicine advocate, to explore the growing impact of environmental factors on men's health. From the risks of microplastics and the benefits of plant-based diets to the carbon cost of prostate procedures, these conversations challenge conventional clinical perspectives and offer practical, planet-conscious solutions for modern urology. Timestamps: 0:30 – The carbon footprint of patient travel 2:05 – How climate change affects urological health 5:46 – Practical advice for urologists 7:53 – MRI-targeted prostate biopsies 10:40 – Emissions associated with MRI procedures
We often panic at the word cancer. For men diagnosed with prostate cancer, it can feel like a threat to their very identity. Many fear it signals the end of their masculinity. But what if there's a better, bolder way to approach treatment? Stephen Petteruti, DO, empowers his patients to “fight prostate cancer like a […]
H&P Disability Direct - Live Answers on the Road to VA Compensation
Here is the link to the Williams Waiver https://www.hillandponton.com/wp-content/uploads/2025/05/Waiver-example.pdfVA Disability Calculator is here https://www.hillandponton.com/va-disability-calculator/Struggling to get the benefits you know you deserve? Get a free case evaluation now! - https://www.hillandponton.com/free-case-evaluation?utm_source=youtube&utm_medium=organic-video&utm_campaign=description&utm_id=Livestream+ShowJoin in our Live VA Disability Q&A Session in which we answer your questions live. We can't get to every single question so we will answer them as they come in. If you have any questions about the VA Disability Benefits process you can ask the question in the comment section when we go live and a little earlier. We are nationwide VA Accredited Disability Lawyers. We can't wait to answer your questions!For a FREE Case Evaluation go here: https://www.hillandponton.com/free-ca...Visit our website at https://www.hillandponton.com/?utm_so...Like us on Facebook at www.facebook.com/HillandPontonFor questions please email us at Info@hillandponton.comSpeakers: Attorney Matthew HillThe content of this YouTube channel is provided for informational purposes only and is not intended to constitute legal advice. You should not rely upon any information contained on this YouTube channel for legal advice. Viewing this YouTube channel is not intended to and shall not create an attorney-client relationship between you and Hill and Ponton, PA. Messages or other forms of communication that you transmit to this YouTube channel will not create an attorney-client relationship and thus information contained in such communications may not be protected as privileged. Hill and Ponton, PA does not make any representation, warranty, or guarantee about the accuracy of the information contained in this YouTube channel or in links to other YouTube channels or websites. This YouTube channel is provided "as is," does not represent that any outcome or result from the viewing of this channel. Your use viewing of this YouTube channel is at your own risk. You enjoy this YouTube channel and its contents only for personal, non-commercial purposes. Neither Hill and Ponton, PA, nor anyone acting on their behalf, will be liable under any circumstances for damages of any kind.
Genetic factors play a critical role in prostate cancer treatment planning, with both germline and somatic mutations guiding therapeutic decisions. The Association of Cancer Care Centers (ACCC) remains committed to improving prostate cancer care and has developed the Metastatic Prostate Cancer Handbook: A Guide to Optimizing Outcomes with Germline and Somatic Testing. In this episode, CANCER BUZZ speaks with Andrea Murphy, FNP-C, ACGN, CGRA, genetics nurse practitioner at Mary Bird Perkins Cancer Center and Amy D. Smith, FNP-BC, director at Meredith & Jeannie Ray Cancer Center, about the impact this handbook has had on patient care delivery, measuring success during the pilot program, and recommendations for sustaining germline and somatic mutation testing in clinical practice. “I think a lot of people were surprised, definitely with germline testing, that all metastatic patients met the criteria [for testing]…”– Andrea (Ani) Murphy, FNP-C, ACGN, CGRA “The other thing that the [hand]book did is [give] us a good outline on what our deficiencies were, where we wanted to go with testing...and just pretty much set it up so that it was easy for us to follow.” – Amy D. Smith, NP-BC “Overall, I think the handbook could give anybody the guidance that they need to set up their own program.” – Amy D. Smith, NP-BC Andrea (Ani) Murphy, FNP-C, ACGN, CGRA Nurse Practitioner – Genetics Mary Bird Perkins Cancer Center Baton Rouge, LA Amy D. Smith, FNP-BC Director Meredith & Jeannie Ray Cancer Center Ivinson Memorial Hospital Laramie, Wyoming Resources: ACCC Metastatic Prostate Cancer Handbook: A Guide to Optimizing Outcomes with Germline and Somatic Testing Understanding the Uptake and Challenges of Genetic Testing Guidelines for Prostate Cancer NCCN Guidelines and Frameworks for Prostate Cancer ACCC Prostate Cancer Resources
Does a high PSA automatically mean you need a biopsy? Think again.In this eye-opening episode, Dr. Stephen Petteruti challenges outdated prostate care protocols and reveals the critical questions every man should ask before making any big decisions.Learn how cutting-edge tools like MRIs and biomarker tracking can often replace invasive biopsies, offering a safer, smarter way to monitor your health. Plus, Dr. Stephen dives into the financial conflicts of interest that might be influencing your care and introduces powerful tests like the calcium score and PSMA PET scan to help you see the bigger picture of your long-term health.Listen now and walk into your next doctor's visit armed with the right questions. Prostate Cancer Alert: What to Ask Your Doctor When Your PSA Is High.Enjoy the podcast? Subscribe and leave a 5-star review!Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com Website: https://www.theprostateprotocol.com/ YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/intellectualmedine Consultation: https://www.theprostateprotocol.com/book-a-consultation Store: https://www.theprostateprotocol.com/store Community: https://www.theprostateprotocol.com/products/communities/v2/fightcancerlikeaman/home Disclaimer: The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com#ProstateCancer #Biopsy #MensHealth
Vanessa Penna left Brazil in 2015 to pursue a PhD in neuroscience at the University of Melbourne, with a scholarship from the Australian government. Six years later, she was awarded the prestigious Global Talent visa, now known as the National Innovation visa (subclass 858), for her scientific work. She now manages clinical trials of new drugs that hold promise for cancer patients. During this journey, she was the third person in the world to be diagnosed with Pure HSP 5A, a rare condition that led her to use a wheelchair. - Vanessa Penna deixou o Brasil em 2015 para cursar doutorado em neurociência na Universidade de Melbourne, com bolsa do governo australiano. Seis anos depois, conquistou o prestigiado visto de Talento Global, agora chamado visto de Inovação Nacional (subclasse 858), por conta de seu trabalho científico. Hoje, ela gerencia ensaios clínicos com novos medicamentos que dão esperança a pacientes com câncer. Durante essa trajetória, foi diagnosticada com uma doença rara, a HSP 5A pura, condição que a levou a usar cadeira de rodas.
In this series, the host Catherine Glass welcomes Stacy Loeb, a renowned urologist and lifestyle medicine advocate, to explore the growing impact of environmental factors on men's health. From the risks of microplastics and the benefits of plant-based diets to the carbon cost of prostate procedures, these conversations challenge conventional clinical perspectives and offer practical, planet-conscious solutions for modern urology.
Today we're talking about prostate cancer prevention….Now before your eyes glaze over or you assume this is just for someone older or someone else, let me assure you: this is something every man over 40 should know — and every man under 40 should be aware of so you can build resilient habits.Because- The good news? You have more control than you might think.Prostate cancer affects 1 in 8 men in the United States. Much the same as the risk women have for breast cancer. But while some factors like age and genetics can't be changed, many of the biggest risks for prostate cancer are lifestyle-related. And the genetics can be turned off.So today, I'm giving you 6 natural, science-backed, and do-able strategies that can help reduce your risk and improve your overall health.These aren't gimmicks. These are things I teach in my practice. And these strategies will support not just your prostate, but your energy, mood, metabolism, and long-term vitality
Today on the Dr. Geo Prostate Podcast, Dr. Geo sits down with Dr. Jacob Meyers, Director of Research and Development at LynxDx, and a scientist with a fascinating background spanning malaria research and genetic testing. Together, they unpack the science behind MyProstateScore 2.0 (MPS2) — a new urine-based test designed to help men and their doctors make smarter, more precise decisions about prostate cancer screening and whether a biopsy is truly needed.In this insightful conversation, you'll learn:The story behind MPS2 and how it moves beyond PSA aloneWhy the test focuses on detecting more aggressive prostate cancerThe unique biomarkers (including TMPRSS2:ERG fusion and KLK3) that set MPS2 apartHow MPS2 can help avoid unnecessary biopsies and even be done at home — no prostate massage requiredFuture directions in biomarker development and what's next for prostate cancer diagnosticsThis episode is full of practical, empowering information for men looking to take control of their prostate health and for clinicians seeking to stay on the cutting edge.
Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News. I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode. Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC. Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings. So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease. So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting. So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting. So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response. So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma. So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025. So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence. So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj. Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer. So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response. These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months. Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup. So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj. Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial. A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion. So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance. So, thank you, Jeanny, for joining me today and sharing your insights. And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Neeraj Agarwal @neerajaiims Dr. Jeanny Aragon-Ching Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis, Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics
UCSF's Dr. Rahul Aggarwal explains the role of clinical trials in advancing prostate cancer treatment and how trial design is evolving to match today's more personalized approaches. He highlights how UCSF has contributed to major prostate cancer therapies and emphasizes the importance of genetic and genomic testing in identifying suitable trials for each patient. Dr. Aggarwal explains the different trial phases, clarifies common myths—such as concerns about placebos—and stresses that trials are considered at every stage of disease. He also discusses efforts to improve access, affordability, and diversity in trial participation, including regional partnerships and digital matching tools. The talk encourages patients to be informed and proactive when considering clinical trials as part of their treatment plan. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40800]
The Cancer Pod: A Resource for Cancer Patients, Survivors, Caregivers & Everyone In Between.
Tell us your thoughts on this episode!In this episode of the Cancer Pod, Dr. Leah Sherman sits down with Dr. David Grew, a board-certified radiation oncologist and founder of Primr, a free digital video resource. They also go into details about prostate cancer, from early detection and PSA testing to the latest advancements in treatment options, including when active surveillance is possible vs. surgery and radiation therapy. Dr. Grew shares how Primr evolved from his inclination to use images to understand and explain medicine. His digitally crafted visual explanations are helping patients understand and navigate their diagnosis and treatment options. Tune in to learn about symptoms, high-risk factors, diagnostic tools like MRIs and genomic testing, and the importance of multiple medical opinions when managing prostate cancer.Click here for Dr. Grew's bio and all social media links to PrimrPrimr Website: https://www.primrmed.com/Direct link to Prostate Cancer Education on PrimrClinical Trial Explainers from Primer:The SABRE TrialThe INDICATE TrialThe CLARIFY TrialSupport the showOur website: https://www.thecancerpod.com Become a member of The Cancer Pod Community! Gain access to live events, exclusive content, and so much more. Join us today and be part of the journey!Email us: thecancerpod@gmail.com Follow @TheCancerPod on: Instagram Bluesky Facebook LinkedIn YouTube THANK YOU for listening!
Featuring perspectives from Dr Neeraj Agarwal, Dr Andrew J Armstrong, Dr Himisha Beltran, Dr Rana R McKay and Dr Fred Saad, moderated by Dr McKay, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Saad (2:12) Current Treatment for Metastatic HSPC — Dr Armstrong (26:12) Role of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Agarwal (49:31) Current and Future Use of Radiopharmaceuticals for mCRPC — Dr McKay (1:12:51) Promising Novel Agents and Strategies Under Investigation for the Management of Prostate Cancer — Dr Beltran (1:36:11) CME information and select publications
This week, we present an inspiring episode for anyone interested in the history, present, and future of prostate cancer care. In this Legends in Urology installment of the BackTable Urology Podcast, Dr. Gerald Andriole joins guest host Dr. Niraj Badhiwala to reflect on a career that has left a lasting impact on the field. --- SYNPOSIS Dr. Andriole shares personal stories from his upbringing in Northeastern Pennsylvania and his journey into medicine. He reflects on his expedited education through Penn State and Jefferson Medical College and his path to urology. He discusses his pivotal work in prostate cancer screening, including the influence of major trials like The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, and traces the evolution of surgical and diagnostic techniques. The conversation also touches on current innovations and the future of prostate cancer management, offering valuable advice for the next generation of urologists. --- TIMESTAMPS 00:00 - Introduction01:59 - From Childhood to Medical School06:48 - Discovering Urology16:52 - Pioneering Prostate Cancer Screening24:07 - The PLCO Study: Design and Challenges28:57 - Controversies and Criticisms in Prostate Cancer Screening33:29 - Evolving Practices in Prostate Cancer Management44:19 - Future of Prostate Cancer Treatment
Last month, former President Joe Biden announced that he had been diagnosed with an aggressive form of prostate cancer. The news sparked a larger conversation about what exactly the best practices are to screen for prostate cancer. Turns out, it's more complicated than it might seem. Host Ira Flatow is joined by oncologist Matthew Cooperberg and statistician Andrew Vickers, who studies prostate cancer screening, to help unpack those complexities.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
On today's episode, Andy & DJ discuss Biden breaking his silence after revealing he's battling with aggressive prostate cancer, James Comey's weird social media approach landing him in hot water, and the video of the Indian version of the Titanic.